Spondyloarthritis & psoriatic arthritis
Impact of C reactive protein on effectiveness of interleukin-17 and tumour necrosis factor inhibitors in axial spondyloarthritis: a Danish nationwide observational study
Authors' conclusion
Higher baseline CRP levels were associated with higher retention for first TNFi but not for first IL-17i. Higher CRP was associated with higher remission rates for both IL-17i and TNFi.
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) in DANBIO initiating first IL-17i or first tumour necrosis factor inhibitor (TNFi), 2015–2024; IL-17i 95% TNFi-experienced, TNFi 99% biologic-naïve601 IL-17i, 2786 TNFi
- Participants
- 3,387 patients
- Exposure
- Baseline C reactive protein (CRP) levels within first IL-17i and within first TNFi
- Outcome
- Treatment retention stratified by baseline CRP
- Follow-up
- 12 months
Methodological detailsDANBIO registry, Kaplan-Meier and Cox regression, stratified by baseline CRP, IL-17i and TNFi analysed separately
- DANBIO registry
- Kaplan-Meier and Cox regression
- Stratified by baseline CRP
- IL-17i and TNFi analysed separately
Main finding
As reported in the abstract
Treatment retention
Hazard ratio (discontinuation) (95% CI)
IL-17i, intermediate CRPvs IL-17i, low CRP
0.96(0.68–1.19)
IL-17i, high CRPvs IL-17i, low CRP
0.90(0.68–1.19)
TNFi, intermediate CRPvs TNFi, low CRP
0.86(0.73–1.02)
- TNFi, high CRP vs TNFi, low CRP
- HR (discontinuation) 0.72 (95% CI 0.62–0.84)
Observational data: associations, not effects.
Further findings
BASDAI remission by baseline CRP (low/intermediate/high)
- IL-17i, remission rates (low/intermediate/high CRP)
- 6%/8%/11%
- TNFi, remission rates (low/intermediate/high CRP)
- 19%/22%/32%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Impact of C reactive protein on effectiveness of interleukin-17 and tumour necrosis factor inhibitors in axial spondyloarthritis: a Danish nationwide observational study. RMD Open. Published 16 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →